November 4, 2015 SOURCE:  REGEN BIOPHARMA INC.

Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy.  Company Intends to Utilize NR2F6 Gene-Silenced Immune Cells to Amplify Body’s Own Anti-Tumor Defenses.